File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

TitleAdvanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy
Authors
Issue Date2014
Citation
Oncologist, 2014 How to Cite?
AbstractThe progress in the development of systemic treatment for advanced pancreatic cancer (APC) has been slow. The main stream treatment remains using chemotherapy including gemcitabine, FOLFIRINOX, and nab-paclitaxel. Erlotinib is the only approved biological therapy with marginal benefit. Studies of agents targeting epidermal growth factor receptor, angiogenesis, and RAS signaling have not been satisfying, and the usefulness of targeted therapy in APC is uncertain. Understanding in molecular processes and tumor biology has opened the door for new treatment strategies such as targeting insulin-like growth factor 1 receptor, transforming growth factor β, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Notch pathway. New directions also include the upcoming immunotherapy and many novel agents that act on the microenvironment. The practice of personalized medicine using predictive biomarkers and pharmacogenomics signatures may also enhance the effectiveness of existing treatment. Future treatment approaches may involve comprehensive genomic assessment of tumor and integrated combinations of multiple agents to overcome treatment resistance. ©AlphaMed Press 2014.
Persistent Identifierhttp://hdl.handle.net/10722/203082
ISSN
2015 Impact Factor: 4.789
2015 SCImago Journal Rankings: 2.391
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChiu, JWYen_US
dc.contributor.authorWong, HYHen_US
dc.contributor.authorLeung, RCYen_US
dc.contributor.authorPang, RWCen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorYau, TCCen_US
dc.date.accessioned2014-09-19T11:29:48Z-
dc.date.available2014-09-19T11:29:48Z-
dc.date.issued2014en_US
dc.identifier.citationOncologist, 2014en_US
dc.identifier.issn1083-7159-
dc.identifier.urihttp://hdl.handle.net/10722/203082-
dc.description.abstractThe progress in the development of systemic treatment for advanced pancreatic cancer (APC) has been slow. The main stream treatment remains using chemotherapy including gemcitabine, FOLFIRINOX, and nab-paclitaxel. Erlotinib is the only approved biological therapy with marginal benefit. Studies of agents targeting epidermal growth factor receptor, angiogenesis, and RAS signaling have not been satisfying, and the usefulness of targeted therapy in APC is uncertain. Understanding in molecular processes and tumor biology has opened the door for new treatment strategies such as targeting insulin-like growth factor 1 receptor, transforming growth factor β, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Notch pathway. New directions also include the upcoming immunotherapy and many novel agents that act on the microenvironment. The practice of personalized medicine using predictive biomarkers and pharmacogenomics signatures may also enhance the effectiveness of existing treatment. Future treatment approaches may involve comprehensive genomic assessment of tumor and integrated combinations of multiple agents to overcome treatment resistance. ©AlphaMed Press 2014.-
dc.languageengen_US
dc.relation.ispartofOncologisten_US
dc.titleAdvanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapyen_US
dc.typeArticleen_US
dc.identifier.emailChiu, JWY: jwychiu@hku.hken_US
dc.identifier.emailWong, HYH: hildahy@hku.hken_US
dc.identifier.emailPang, RWC: robertap@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.authorityChiu, JWY=rp01917en_US
dc.identifier.authorityPang, RWC=rp00274en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.doi10.1634/theoncologist.2012-0131-
dc.identifier.pmid25117068-
dc.identifier.scopuseid_2-s2.0-84906976007-
dc.identifier.hkuros236944en_US
dc.identifier.isiWOS:000341412300007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats